Microbot Medical (MBOT) - Pangali EV/EBITDA

The EV/EBITDA price trend reflected below is 0.00. Microbot Medical Inc. (MBOT) is expanding the application of its robots to cover neurosurgery and cardiology, while mitigating regulatory risks through expansion into foreign markets. Innovative vascular microrobots provide the company with exceptional market power and the ability to maintain flexible pricing power. Currently, management's success depends on clinical test results and the acquisition of strategic partners.

This ratio is calculated as the total enterprise value, including net debt, divided by earnings before depreciation and amortization. The metric determines the payback period of assets, where extreme values signal either overvaluation or financial insolvency. For Microbot Medical Inc. (MBOT) and its innovative Liberty system, this calculation is critical when assessing the capital intensity of robotic surgery development. By analyzing the current EV/EBITDA trend of Microbot Medical Inc. (MBOT), an investor can evaluate the market value of these technologies.